Akero shares double after preliminary results from mid-stage trial for liver disease drug

(Reuters) – Akero Therapeutics shares gained 106% before the bell on Monday after the company reported results from a mid-stage trial studying its lead drug in patients with a type of liver disease.

The experimental drug efruxifermin is being studied in patients with scarring due to a type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis.

(Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri)